191604-81-6

Basic information

• Product Name: methyl 5-(hydroxymethyl)-2-methoxybenzoate
• Synonyms: methyl 5-(hydroxymethyl)-2-methoxybenzoate
• CAS NO: 191604-81-6
• Molecular Weight: 196.203
• Mol File: 191604-81-6.mol

Chemical Properties

• CAS DataBase Reference: methyl 5-(hydroxymethyl)-2-methoxybenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 5-(hydroxymethyl)-2-methoxybenzoate(191604-81-6)
• EPA Substance Registry System: methyl 5-(hydroxymethyl)-2-methoxybenzoate(191604-81-6)

Safety Data

• Hazardous Substances Data: 191604-81-6(Hazardous Substances Data)

Upstream product

• 78515-16-9 methyl 5-formyl-2-methoxybenzoate 

Downstream Products

• 98165-65-2 methyl 5-(bromomethyl)-2-methoxybenzoate 
• 1369423-46-0 (R)-methyl 2-methoxy-5-((4-methyl-5-oxo-2-phenyl-4,5-dihydrooxazol-4-yl)methyl)benzoate 
• 1369423-50-6 methyl 5-(((diphenylphosphoryl)oxy)methyl)-2-methoxybenzoate 
• 7252-24-6 3-carbomethoxy-4-methoxybenzyl chloride 
• 330861-69-3 5-carbamoylmethyl-2-methoxy-N-(4-trifluoromethylbenzyl)benzamide 
• 330861-68-2 5-cyanomethyl-2-methoxy-N-(4-trifluoromethylbenzyl)benzamide 
• 24550-59-2 5-cyanomethyl-2-methoxy-benzoic acid methyl ester 
• 24550-58-1 5-cyanomethyl-2-methoxybenzoic acid 

Relevant articles and documents

Design, synthesis and evaluation of substituted phenylpropanoic acid derivatives as peroxisome proliferator-activated receptor (PPAR) activators: Novel human PPARα-selective activators

A series of substituted phenylpropanoic acid derivatives was prepared as part of a search for subtype-selective human peroxisome proliferator-activated receptor (PPAR) activators. Structure-activity relationship studies indicated that the substituent at the α-position of the carboxyl group plays a key role in determining the potency and the selectivity for PPAR transactivation.

PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE

The present invention provides a compound represented by formula [I] shown below or a pharmaceutically acceptable salt thereof that has an inhibitory effect on 20-HETE producing enzyme. (in formula [I] above, the structure represented by formula [II] below: represents any of the structures represented by formula group [III] below: R1, R2, R3, and R4 independently represent a hydrogen atom, a fluorine atom, methyl, or the like, R5 represents any of the structures represented by formula group [IV]:

Benzylic phosphates as electrophiles in the palladium-catalyzed asymmetric benzylation of azlactones

Palladium-catalyzed asymmetric benzylation has been demonstrated with azlactones as prochiral nucleophiles in the presence of chiral bisphosphine ligands. Benzylic electrophiles are utilized under two sets of reaction conditions to construct a new tetrasubstituted stereocenter. Electron density of the phenyl ring dictates the reaction conditions, including the leaving group. The reported methodology represents a novel asymmetric carbon-carbon bond formation in an amino acid precursor.

SUBSTITUTED 4-(1H-BENZIMIDAZOL-2-YL)[1,4]DIAZEPANES USEFUL FOR THE TREATMENT ALLERGIC DISEASES

The present invention relates to novel 4-(1H-benzimidazol-2-yl)[1,4] diazepane derivatives of formula (1): and stereoisomers thereof, and pharmaceutically acceptable salts thereof which are useful as histamine receptor antagonists and tachykinin receptor antagonist. Such antagonists are useful in the treatment of allergic rhinitis, including seasonal rhinitis and sinusitis; inflammatory bowel diseases, including Crohn's disease and ulcerative colitis; asthma; bronchitis; and emesis.

Novel substituted 4-(1H-benzimidazol-2-yl) [1,4]diazepanes useful for the treatment of allergic diseases

The present invention relates to novel 4-(1H-benzimidazol-2-yl)[1,4]diazepane derivatives of formula and stereoisomers thereof, and pharmaceutically acceptable salts thereof which are useful as histamine receptor antagonists and tachykinin receptor antagonist. Such antagonists are useful in the treatment of allergic rhinitis, including seasonal rhinitis and sinusitis; inflammatory bowel diseases, including Crohn's disease and ulcerative colitis; asthma; bronchitis; and emesis.

Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic disease

The present invention relates to novel 4-(1H-benzimidazol-2-yl)[1,4]diazepane derivatives of formula (1): and stereoisomers thereof, and pharmaceutically acceptable salts thereof which are useful as histamine receptor antagonists and tachykinin receptor antagonist. Such antagonists are useful in the treatment of allergic rhinitis, including seasonal rhinitis and sinusitis; inflammatory bowel diseases, including Crohn's disease and ulcerative colitis; asthma; bronchitis; and emesis.

Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases

The present invention relates to novel substituted piperidine derivatives of formula (1), stereoisomers thereof, and pharmaceutically acceptable salts thereof which are useful as histamine receptor antagonists and tachykinin receptor antagonist. Such antagonists are useful in the treatment of allergic rhinitis, including seasonal rhinitis and sinusitis; inflammatory bowel diseases, including Crohn's disease and ulcerative colitis; asthma; bronchitis; and emesis.